Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Diabetes Mellitus, Type 2
Phase NA
Enrollment 25
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to compare the effects of peer coaching models in older adults with unmanaged type two diabetes. The main questions it aims to answer are: * Are peer coaching models effective at promoting Type 2 Diabetes Mellitus self-management? * If effective, which facets of the peer model are most effective? Peer coaches will undergo peer coach training. * Reach out to peer participants on a weekly/biweekly time frame to discuss self-management and goal setting. * Retain records of contact, topics discussed, and general notes on interactions. Researchers will compare differences in the frequency of contact, as well as how peer coaches were matched to peer participants to see if efficacy of the intervention is altered between groups.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Factorial Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Behavioral: Peer Coaching - Peer Participants A — Peer participants in group A will be contacted by peer coaches on a weekly basis.
  • Behavioral: Peer Coaching - Peer Participants B — Peer participants in group B will be contacted by peer coaches on a bi-weekly basis.
  • Behavioral: Peer Coaching - Peer Participants C — Peer participants in group C will be contacted by peer coaches on a weekly basis.
  • Behavioral: Peer Coaching - Peer Participants D — Peer participants in group D will be contacted by peer coaches on a bi-weekly basis.

Primary Outcomes

  • Number of Participants with Change in A1c (Collected at Baseline, 6 months (at the end of the intervention), 3-months and 6-months post-intervention.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-11-20
Completion: 2027-03-31
Eligibility
Age: 55 Years and older
Sex: ALL
Volunteers: false
Enrollment: 25 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The University of Texas Medical Branch, Galveston
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Principal Investigators:
  • Brittany L. Smalls, PhD (PRINCIPAL_INVESTIGATOR) - University of Texas Medial Branch
Contact Information
Study Contact:
Brittany L. Smalls, PhD
409-772-1011
blsmalls@utmb.edu
Kindness C. Akwari, MS
502-627-0591
kcakwari@utmb.edu
Alecia Johnson
270-781-2381
alecia.johnson@bradd.org
Barren River Area Development District
Interventions
  • Behavioral: Peer Coaching - Peer Participants A — Peer participants in group A will be contacted by peer coaches on a weekly basis.
  • Behavioral: Peer Coaching - Peer Participants B — Peer participants in group B will be contacted by peer coaches on a bi-weekly basis.
  • Behavioral: Peer Coaching - Peer Participants C — Peer participants in group C will be contacted by peer coaches on a weekly basis.
  • Behavioral: Peer Coaching - Peer Participants D — Peer participants in group D will be contacted by peer coaches on a bi-weekly basis.
Study Locations (2 sites)
Barren River Area Development District, Bowling Green, Kentucky 42101 United States
UK HealthCare, Hazard, Kentucky 41701 United States
Eligibility Criteria
Inclusion Criteria: * Age greater than or equal to 55 years * Resident in Rural Kentucky * Positive diagnosis of Type 2 Diabetes Mellitus * HbA1c less than 7.5 for peer coaches * Passing score on cognitive assessment administered by study personnel * English Speaking Exclusion Criteria: * Age less than 55 years * Not a resident of a Rural Kentucky County * No Type 2 Diabetes Mellitus Diagnosis * Cognitive Impairment * Non-English Speaking
Conditions Asthma
Phase PHASE3
Enrollment 1100
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this clinical study is to learn about the safety and effects of the study medicine (called tilrekimig) for the potential treatment of severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life of people who are affected. The study is seeking participants who: * Have a history of severe asthma for at least 12 months * Have had at least 2 asthma attacks (also known as exacerbations) within the last 12 months All participants will be given shots of study medicine or a placebo at the study clinic. Tilrekimig or the placebo will be given about every 4 weeks during the study. The study will compare the experiences of people receiving tilrekimig to those people who receive the placebo. This will help determine if tilrekimig is safe and effective.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: tilrekimig — subcutaneous injection
  • Other: Placebo — subcutaneous injection

Primary Outcomes

  • Annualized asthma exacerbation rate over 52 weeks (Baseline through Week 52)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-09-30
Completion: 2029-08-30
Eligibility
Age: 12 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 1100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Pfizer
Principal Investigators:
  • Pfizer CT.gov Call Center (STUDY_DIRECTOR) - Pfizer
Contact Information
Study Contact:
Pfizer CT.gov Call Center
1-800-718-1021
ClinicalTrials.gov_Inquiries@pfizer.com
Interventions
  • Drug: tilrekimig — subcutaneous injection
  • Other: Placebo — subcutaneous injection
Study Locations (3 sites)
Allergy and Clinical Immunology Associates, Pittsburgh, Pennsylvania 15241 United States
Orion Clinical Research, Austin, Texas 78759 United States
DM Clinical Research, Tomball, Texas 77375 United States
Eligibility Criteria
Inclusion Criteria Must meet the following asthma criteria: 1. History of persistent, severe asthma for at least 12 months prior to screening as defined by recognized international and / or local guidelines. 2. Must have experienced at least 2 asthma exacerbations requiring treatment with systemic steroids (oral or parenteral) for 3 consecutive days or more; an emergency room or urgent care visit (\<24 hours) that is due to asthma and requires use of systemic corticosteroids as noted above; or an in-patient hospitalization (an admission to an in-patient hospital or evaluation and treatment in a healthcare facility for ≥24 hours) due to asthma with within 12 months of the screening visit. 3. Positive bronchodilator responsiveness of FEV1 or FVC \>10% of the participant's predicted value at 15 - 30 minutes (or as consistent with local treatment practices) after inhaling 400 µg of salbutamol/albuterol (or equivalent SABA) at least once for spirometry conducted during screening period. Other Inclusion Criteria: 4. Maintenance treatment of a medium-to-high dose ICS plus an additional controller (eg, LABA) consistent with current GINA and / or local guidelines for at least 12 months (and on a stable dose for 3 months prior to screening). Exclusion Criteria Participants are excluded from the study if any of the following criteria apply: Medical Conditions: 1. Evidence of lung disease(s) other than asthma, either clinical evidence, spirometry, or imaging (Chest X-ray, CT, MRI) within 12 months of the screening visit, as per local standard of care, including but not limited to, chronic obstructive pulmonary disease, other emphysematous lung disease such as alpha-1 antitrypsin disease, cystic fibrosis, emphysema, pulmonary fibrosis, Churg-Strauss syndrome, allergic bronchopulmonary aspergillosis, sarcoidosis, pulmonary embolism. 2. Any psychiatric condition including any active suicidal ideation in the past year or suicidal behavior in the past 5 years that may increase the risk of study participation or, in the investigator's judgement, make the participant inappropriate for the study. Prior/Concomitant Therapy: 3. Use of any prohibited concomitant medication(s) or unwillingness or inability to use a required concomitant medication(s). Treatment with any dose level of systemic (oral, intraarticular, or injectable) corticosteroids within 28 days of the screening visit. 4. Prior or concurrent treatment with either approved or experimental biologic treatment (such as inhibitors of IL-4Ralpha, TSLP, OX40/OX40L, IL-13, IL-33 / ST2) or targeted synthetic drugs for the treatment of asthma or other type 2 inflammatory diseases, including but not limited to: AD, EoE, CRS. 5. Prior (within 12 weeks prior to Screening Visit 1) or planned concomitant treatment with immunoglobulin supplementation (eg, IV Ig or SC Ig). 6. Bronchial thermoplasty within the previous 24 months. Prior/Concurrent Clinical Study Experience: 7. Administration of an investigational drug product within 30 days or 5 half lives preceding the screening visit (whichever is longer). Previous participation in other tilrekimig studies or participation in studies of other investigational products (drug or vaccine) at any time during this study.
Conditions Chronic Rhinosinusitis With Nasal Polyps
Phase Not Applicable
Enrollment 180
Locations 1 sites
Compensation Compensation or reimbursement is mentioned in the public study record; confirm details with the study team.
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

This study is a pragmatic, real-life, observational study recruiting adult patients with chronic rhinosinusitis with nasal polyposis who are eligible to start biologicals as standard treatment. The aim of this study is to observe the long-term outcomes of biologicals in CRSwNP patients with or without comorbid asthma in 'real life'. Moreover, the investigators will gain insight into the mechanisms of biologicals in the local and systemic immunity of these patients and investigate novel local and systemic biomarkers and predictors of response.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Biological: Mepolizumab — Monoclonal antibodies

Primary Outcomes

  • Clinical characteristics (24 months)
  • Clinical characeristics (24 months)
  • Local nasal immunity (24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-03-01
Completion: 2030-12-31
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Ghent
Principal Investigators:
  • Philippe Gevaert, Prof. Dr. (PRINCIPAL_INVESTIGATOR) - University Hospital, Ghent
Contact Information
Study Contact:
Manon Blauwblomme, Masters
+32 09 332 23 98
manon.blauwblomme@ugent.be
Philippe Gevaert, Prof. Dr.
Manon Blauwblomme, Masters
+32 09 332 23 95
manon.blauwblomme@ugent.be
Ghent University Hospital
Interventions
  • Biological: Mepolizumab — Monoclonal antibodies
Study Locations (1 sites)
Ghent University Hospital, Ghent, 9000 Belgium
Eligibility Criteria
Inclusion Criteria: Patients must meet the following criteria to be eligible for the enrolment in the study: * Signed informed consent form (ICF), * Age between 18 and 80 years at time of signing ICF, * Able to comply with the study protocol, in the investigator's judgment, * In group one: patients with severe allergic and/or eosinophilic asthma, defined by being currently treated with a biological (SoC) OR starting treatment with a biological (SoC). * In group two: patients with CRSwNP with or without asthma, defined by starting treatment with a biological (SoC) and fulfill the criteria for reimbursement of a biological therapy Exclusion Criteria: Patients who do not meet the reimbursement criteria of a biological therapy cannot participate in the study.
Conditions Severe Asthma
Phase Not Applicable
Enrollment 600
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

The 3TR-ABC study is a multicentre observational prospective cohort study platform that follows patients with severe asthma from the start of biological therapy and three years onwards. In the 3TR-ABC platform, individual studies are conducted on specific biologics, using aligned study designs. The aim of the study is to assess response to treatment and examine clinical characteristics, biomarkers, and immunological mechanisms related to response, including remission and non-response, that might be new targets or explanations for insufficient treatment. Patients will be extensively characterized at baseline and then followed throughout the years with formal clinical and biological assessment at 4, 16, 52 weeks, and 2, 3 years. Based on the response to treatment, patients will be stratified into remission, clinical responders, and non-responders, and pre-treatment biomarker profiles obtained at the baseline visit will be compared, as well as the immunological response to treatment. Healthy individuals and patients with mild/moderate controlled asthma are included as reference groups and will undergo the same baseline visit as patients with severe asthma. Several bio-samples, to perform multi-omic analysis, will be taken to examine biological pathways associated with response and non-response to biologics.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Change in Asthma Control Questionnaire 5 (ACQ-5) score (1 year, 2 and 3 years)
  • Change in post- broncodilator Forced Expiratory Volume after 1 second (FEV1) (1 year, 2 and 3 years)
  • Absense of exacerbations (1 year, 2 and 3 years)
  • No usage of oral corticosteroids in the previous 12 months (1 year, 2 and 3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-01-10
Completion: 2033-08
Eligibility
Age: Not reported
Sex: ALL
Volunteers: true
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators: Bispebjerg Hospital, University Hospitals, Leicester, Karolinska Institutet, University Medical Center Groningen
Principal Investigators:
  • Anke-Hilse Maitland-van der Zee, Prof.Dr. (PRINCIPAL_INVESTIGATOR) - Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
  • Peter Bonta, MD (PRINCIPAL_INVESTIGATOR) - Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
  • Celeste Porsbjerg, Prof.Dr. (PRINCIPAL_INVESTIGATOR) - Bispebjerg Hospital
Contact Information
Study Contact:
Susanne Vijverberg, Dr.
0031 (0)20-566 27 63
s.j.vijverberg@amsterdamumc.nl
Peter Bonta, MD
p.i.bonta@amsterdamumc.nl
Nanna Dyhre-Petersen, Msc
nanna.dyhre-petersen@regionh.dk
Bispebjerg Hospital
Interventions
N/A
Study Locations (2 sites)
Bispebjerg Hospital, Copenhagen, 2400 Denmark
Amsterdam University Medical Center, Amsterdam, North Holland 1105AZ Netherlands
Eligibility Criteria
Inclusion Criteria: * Patients with severe asthma that requires High dose ICS (corresponding to minimum 1600 micrograms Budesonide per day) + either LABA, LTRA, or LAMA OR Fixed Prednisolone treatment (OCS) minimum 50% of the time. Minimum 2 exacerbations in the last year or fixed Prednisolone treatment (OCS) minimum 50% of the time OR ACQ\>1.5 AND Fulfils national criteria for specific biologic treatment. * Patients with mild/moderate asthma that requires Low/Medium dose of ICS/LABA +/- LTRA. ACQ \< 1.5. No exacerbations in the last year or need of Prednisolone treatment (OCS). Markers of T2 inflammation (B-eos ≥ 0.15 actual or ≥ 0.30 the last year or Sputum eos ≥ 3%, FeNO ≥ 25, allergens positivity). Not direct candidate for treatments with monoclonal antibodies. * Healthy volunteers that reports no respiratory diseases, No history of asthma or respiratory symptoms, normal lung function. No history of allergies. No lower or upper respiratory infections in the past 4 weeks. Exclusion Criteria: * Patients with severe asthma: 1. Known hypersensitivity to the active substance or any of the excipients 2. Participation in an interventional clinical trial within 3 months of visit 1 or receipt of any investigational medicinal product within 3 months or 5 half-lives. Participation in other observational studies is acceptable if in the view of the investigator it will not impact on the study outcomes. 3. Other clinically significant medical disease or uncontrolled concomitant disease that is likely, in the opinion of the investigator, to require a change in therapy or impact the ability to participate in the study. * Patients with mild/moderate asthma: 1. Unable to understand written information due to language barriers. 2. Unable to give informed consent, i.e., patients who are incapable. 3. Show sign of symptoms of uncontrolled asthma (ACQ score higher than 1.5, OCS use, history of exacerbations within the past year). * Healthy volunteers: 1. Unable to understand written information due to language barriers. 2. Unable to give informed consent, i.e., patients who are incapable.
Conditions Asthma
Phase Not Applicable
Enrollment 2000
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

There is limited information on genetics associated with asthma in Chinese. An earlier meta-analysis found that ADAM33, FcεRIb, RANTES, TNF-a, ACE, b2-AR, IL-4R and IL-13 genes could be proposed as asthma susceptible genes in the Chinese population. However, given the limited number of studies, more data are required to validate these associations. Future research must address key issues such as the broad clinical variability of asthma and the underrepresentation of populations of non-European heritage. Endotype-specific SNPs and unique biological insights may be obtained by conducting GWAS/EWAS on homogeneous populations of more therapy-resistant T2-low, adult-onset, obesity-associated asthma or asthma with particular co-morbidities. The primary objective is to investigate the association between genetic polymorphisms and various severities of asthma.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Genetic: No intervention — No intervention

Primary Outcomes

  • association between genetic polymorphisms and various severities of asthma (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-03-01
Completion: 2029-01-04
Eligibility
Age: 18 Years – 100 Years
Sex: ALL
Volunteers: true
Enrollment: 2000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chinese University of Hong Kong
Principal Investigators:
  • David SC Hui (STUDY_DIRECTOR) - Chinese University of Hong Kong
Contact Information
Study Contact:
David SC Hui, MD
35053133
dschui@cuhk.edu.hk
David S Hui, MD
35053133
dschui@cuhk.edu.hk
The Chinese University of Hong Kong
fanny WS Ko, MD
35053133
fannyko@cuhk.edu.hk
The Chinese University of Hong Kong
Interventions
  • Genetic: No intervention — No intervention
Study Locations (2 sites)
The Chinese University of Hong Kong, Hong Kong, New Territories Hong Kong
The Chinese University of Hong Kong, Hong Kong, Hong Kong
Eligibility Criteria
Inclusion Criteria: * • All patients with confirmed diagnosis of asthma (defined as those with a consistent history and prior documented evidence of variable airflow obstruction, with evidence of an increase in FEV1 greater than 12% or 400 mL following bronchodilator or bronchial hyperresponsiveness on bronchial provocation testing, when stable) 12 * Able to sign written informed consent form to participate in the study. Exclusion Criteria: * • Patients currently with acute exacerbation of asthma by GINA guideline. (For subjects with asthma exacerbation, they can join the study after 6 weeks post recovery from the exacerbation.) * Patients with respiratory diseases that can show similar symptoms to chronic airway diseases such as bronchiectasis, tuberculosis(TB)-destroyed lung parenchyma, endobronchial TB, and lung cancer, or those who have history of these diseases based on physician's judgment. * Patients currently diagnosed with pneumonia and acute bronchitis. For control subject: the inclusion will be having no clinical diagnosis of asthma.

SMART@Home Feasibility Trial

NCT06159127
Recruiting
Conditions Asthma, Asthma in Children
Phase NA
Enrollment 25
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

The proposed research addresses the limitations or lack of a digital platform to provide remote care of medically complex patients. Previous attempts have had poor clinical validity and suffered lack of patient engagement. The study team will deconstruct the previously implemented SMART platforms to create a roadmap, platform, and template to guide clinicians to create new tools. Results from Phase 1 of this project highlighted the need for connectivity between the SMART@Home app and Bluetooth-enable devices to provide objective disease activity data as well as integration with Epic electronic health record so that providers can use the data to inform treatment planning and decision making. A subsequent pilot user validation trial is also needed to confirm development goals were met. Conducting a pilot user validation trial of the SMART@Home asthma tracker, spirometer, and action plan is the purpose of the next phases of this study. A beta test the SMART@Home Asthma Tracker and asthma action plan algorithm will take place with approximately 8 participants. Beta testing will have participants record simulated increases in symptoms to ensure appropriate levels of care is communicated via the app. Then, a group of 40 adolescent (ages 12-17) patients with asthma for a 6-month pilot Randomized Control Trial (RCT). Participants will be randomized into either the IMAAP SMART@Home (n=20) or control (n=20) groups following the completion of baseline measures to test the interactive asthma action plan functionality and impact.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: SMART@Home — Daily medication and diary completion reminders are provided to participants. Additional educational content regarding self-management skills will be provided.

Primary Outcomes

  • Medication Adherence (6 months)
  • Number of days app used (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-09-09
Completion: 2027-07-31
Eligibility
Age: 12 Years – 18 Years
Sex: ALL
Volunteers: false
Enrollment: 25 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Children's Hospital Medical Center, Cincinnati
Principal Investigators:
  • Kevin Hommel, PhD (PRINCIPAL_INVESTIGATOR) - Children's Hospital Medical Center, Cincinnati
  • Rachelle Ramsey, PhD (STUDY_CHAIR) - Children's Hospital Medical Center, Cincinnati
  • Matt Wortman, PhD (STUDY_CHAIR) - Children's Hospital Medical Center, Cincinnati
Contact Information
Study Contact:
Kevin Hommel, PhD
513-803-0407
kevin.hommel@cchmc.org
Jessica King, BA
513-803-0920
jessica.king1@cchmc.org
Kevin, PhD
Cincinnati Children's Hospital Medical Center
Interventions
  • Behavioral: SMART@Home — Daily medication and diary completion reminders are provided to participants. Additional educational content regarding self-management skills will be provided.
Study Locations (1 sites)
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229 United States
Eligibility Criteria
Inclusion Criteria: * Patients diagnosed with a chronic medical condition requiring regular treatment, i.e., asthma * Ages 12-18 * English fluency for patient and caregiver Exclusion Criteria: * Diagnosis of pervasive developmental disorder in patient or caregiver as determined by medical chart review * Diagnosis of serious mental illness (e.g., schizophrenia) in patient or caregiver as determined by medical chart review
Conditions Childhood Asthma, Asthma Control, Asthma...
Phase NA
Enrollment 351
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if adding Air Quality Index (AQI) information to asthma action plans works to improve asthma outcomes in children. It will also learn about children with asthma who report being more sensitive to outdoor air pollution. The main questions it aims to answer are: * Does adding either information about the EPA-AQI or commercial AQI improve asthma outcomes over time? * Are there changes in nasal gene expression in children with asthma who report they are more sensitive to outdoor air pollution? Researchers will compare EPA-AQI and the commercial-AQI groups to a control group to either AQI works to improve asthma. Participants will: * Receive standardized outdoor air pollution education and an asthma action plan * Provide nose and blood specimens * Have visits every 4 weeks for 48 weeks, 10 will be conducted by telephone calls and 3 visits will be in person.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: EPA-AQI — The EPA-AQI group will receive standardized outdoor air pollution education, standardized AQI education, instructions for AQI usage, and an asthma action plan containing information specific for the EPA-AQI, and will demonstrate the ability to navigate to the EPA-AQI via smartphone app or website.
  • Behavioral: Commerical-AQI — The commercial-AQI group will receive standardized AQI education, instructions for commercial-AQI usage, and an asthma action plan containing information specific for the commercial-AQI, and will demonstrate the ability to navigate to the commercial-AQI via smartphone or website.
  • Behavioral: Education and plan — Standardized outdoor air pollution education and standard asthma action plan

Primary Outcomes

  • Change in asthma control scores, over-time, between groups (Baseline through 48 weeks, measured at 4 week intervals)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-24
Completion: 2030-01
Eligibility
Age: 8 Years – 17 Years
Sex: ALL
Volunteers: false
Enrollment: 351 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Pittsburgh
Collaborators: National Institute of Environmental Health Sciences (NIEHS)
Principal Investigators:
  • Franziska Rosser, MD MPH (PRINCIPAL_INVESTIGATOR) - University of Pittsburgh
Contact Information
Study Contact:
Pediatric Asthma Center
877-296-9026
franziska.rosser2@chp.edu
Interventions
  • Behavioral: EPA-AQI — The EPA-AQI group will receive standardized outdoor air pollution education, standardized AQI education, instructions for AQI usage, and an asthma action plan containing information specific for the EPA-AQI, and will demonstrate the ability to navigate to the EPA-AQI via smartphone app or website.
  • Behavioral: Commerical-AQI — The commercial-AQI group will receive standardized AQI education, instructions for commercial-AQI usage, and an asthma action plan containing information specific for the commercial-AQI, and will demonstrate the ability to navigate to the commercial-AQI via smartphone or website.
  • Behavioral: Education and plan — Standardized outdoor air pollution education and standard asthma action plan
Study Locations (1 sites)
UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania 15224 United States
Eligibility Criteria
Inclusion Criteria: * A healthcare provider diagnosis of persistent asthma (Steps 2-5 as defined by US guidelines) or intermittent asthma (Step 1) + at least one severe asthma exacerbation (defined by American Thoracic Society (ATS)/European Respiratory Society (ERS) criteria as requiring at least 3 days of systemic steroids or an Emergency Department/Urgent Care visit requiring systemic steroids) in the prior 12 months * Home access to a smartphone or internet * Primary residence in Allegheny County, PA * One participant per household * Age 8 -17 years * Healthcare provider evaluation for asthma in the prior year Exclusion Criteria: * Diagnosis of other active chronic respiratory diseases (e.g., cystic fibrosis, bronchopulmonary dysplasia, etc.) * Neuromuscular disorder * Chronic disorder limiting independent ambulation (e.g., spastic quadriplegia, etc.) * Cyanotic heart disease * Plans to relocate from Allegheny County, PA in the next year (12 months) * Use of intranasal or oral/intramuscular/intravenous corticosteroids 4 weeks prior to randomization * Current participation in another asthma intervention trial
Conditions Asthma
Phase PHASE2
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of the study is to enroll participants with uncontrolled asthma to evaluate the large and small airways and drug delivery utilizing two study drugs: * Beclometasone dipropionate/Formoterol fumarate dihydrate/Glycopyrronium bromide (BDP/FF/G) or Trimbow * Fluticasone furoate/Umeclidinium/Vilanterol (FluF/UMEC/VI ) or Trelegy Ellipta

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate pMDI — pMDI,100/6/12.5 mcg per inhalation
  • Drug: Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder — Dry Powder Inhaler,100/62.5/25 mcg per inhalation

Primary Outcomes

  • Evaluate the effect of extrafine beclomethasone dipropionate/formoterol fumarate /glycopyrrolate compared with non-extrafine fluticasone furoate/ umeclidinium/vilanterol on ventilation defect percentage utilizing 129Xenon MRI. (8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-03-15
Completion: 2030-12-31
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Alabama at Birmingham
Contact Information
Study Contact:
Elizabeth Plan, RRT
205-975-5294
epkennedy@uabmc.edu
Surya Bhatt, MD, MSPH
205-934-5555
sbhatt@uabmc.edu
Elizabeth Plan, RRT
205-975-5294
epkennedy@uabmc.edu
The University of Alabama at Birmingham
Interventions
  • Drug: Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate pMDI — pMDI,100/6/12.5 mcg per inhalation
  • Drug: Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder — Dry Powder Inhaler,100/62.5/25 mcg per inhalation
Study Locations (1 sites)
The University of Alabama at Birmingham, Birmingham, Alabama 35233 United States
Eligibility Criteria
Inclusion Criteria: * Subject's written informed consent obtained prior to any study-related procedure. * Patients aged ≥ 18 and ≤ 75 years * Confirmed diagnosis of asthma (patients must have a documented history of asthma for at least 1 year with diagnosis before the age of 40 and/or pre-bronchodilator FEV1 between 50-80% of their predicted normal value, after appropriate washout from bronchodilators) * Symptomatic on ICS/LABA treatment with ACT \<20 * No exacerbations in the past 3 months requiring treatment with systemic corticosteroids or emergency department visit/ in-patient hospitalization * The ability to be trained and correctly use a pressurized Meter Dose Inhaler (pMDI) and Dry Powder Inhaler (DPI) * To have a cooperative attitude and the ability to perform the required outcomes measurements (e.g. spirometry maneuvers in sitting and supine position) and the ability to understand the risks involved * WOCBP fulfilling one of the following criteria: 1. WOCBP with fertile male partners: they and/or their partner must be willing to use a highly effective birth control method from the signature of the informed consent and until the follow-up visit or 2. WOCBP with physician confirmed non-fertile male partners (contraception is not required in this case). * Female patients of non-childbearing potential defined as physiologically incapable of becoming pregnant (i.e. post-menopausal or permanently sterile, e.g. amenorrheic for ≥12 consecutive months without alternative medical cause). Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. If indicated, as per investigator's request, post-menopausal status may be confirmed by follicle-stimulating hormone levels (according to local laboratory ranges). Exclusion Criteria: * Pregnant or lactating female * Patients who had an exacerbation, defined as a sustained and acute deterioration of subject's symptoms and signs (dyspnea, cough and/or sputum production/purulence) that was either moderate, i.e. require treatment with systemic (oral/IV/IM) corticosteroids and/or antibiotics, or severe, i.e. require hospitalization, if their associated treatment/hospitalization occurred within 3 months prior to V1 * Inability to carry out pulmonary lung function testing, to comply with study procedures or with study treatment intake * History of near fatal asthma or of a past hospitalization for asthma in intensive care unit which, in the judgement of the Investigator, may have placed the patient at undue risk * Patients using systemic corticosteroid medication in the 4 weeks or slow-release corticosteroids in the 12 weeks, prior to screening * Patients who suffer from COPD as defined by the current Global Initiative for Chronic Obstructive Lung Disease (GOLD) document * History of a diagnosis of cystic fibrosis, bronchiectasis or alpha-1 antitrypsin deficiency, or any other significant lung disease which may have interfered with study evaluations * Current smokers or current use of electronic cigarettes or ex-smokers with total cumulative exposure equal or more than 10 pack-years or having stopped smoking one year or less prior to screening visit * Patients who had clinically significant cardiovascular condition according to investigator's judgement, such as but not limited to: congestive heart failure (NYHA class \>2), acute ischemic heart disease in the last year prior to study screening, history of sustained cardiac arrhythmias or sustained and non-sustained cardiac arrhythmias diagnosed in the last 6 months (sustained meant lasting more than 30 seconds or ending only with external action, or led to hemodynamic collapse; non-sustained meant \>3 beats \<30 seconds, and or ending spontaneously, and or asymptomatic), high degree impulse conduction blocks (\>2nd degree atrioventricular block type 2). Similarly, patients affected by persistent, long standing or paroxysmal AF were not considered for enrollment * Patients who are unable to undergo imaging procedures for CT scans or MRI or demonstrate intolerance to Xenon gas * Patients who have participated in a recent therapeutic trial (within past 6 months) * Patients who have a milk protein allergy
Conditions Asthma
Phase NA
Enrollment 200
Locations 10 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

Severe asthma is a complex and heterogeneous disease. Patients with severe asthma can present with different types of airway inflammation, and are often accompanied by a variety of comorbidities and risk factors. Identification of potentially modifiable factors affecting prognosis, that is, "treatable characteristics", and individualized bundle management based on these characteristics may help to improve the quality of life of patients with asthma and improve the level of asthma control. Through joint research, this project aims to evaluate the treatable characteristics of asthma in patients with severe asthma in tertiary hospitals across the country, including lung function, fractional exhaled nitric oxide, blood routine, allergen IgE, chest CT, and a detailed questionnaire. The distribution of treatable characteristics of patients with severe asthma and its impact on the quality of life or asthma control level of patients were investigated. For patients with severe asthma, multidisciplinary consultation and shared decision-making were used to establish an individualized bundle management model based on the treatable characteristics of severe asthma. A 6-month randomized parallel controlled clinical trial was conducted to determine whether this model was superior to conventional management in improving the quality of life or asthma control in patients with severe asthma. The implementation of this project will build a new model of individualized management of severe asthma based on treatable characteristics and improve the management level of severe asthma

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Individualized cluster management — Individualized cluster management for treatable traits
  • Procedure: Routine asthma treatment — Routine asthma treatment according to current guidelines

Primary Outcomes

  • Changes from baseline in asthma quality of life score (AQLQ) at 6 months (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-02-01
Completion: 2029-01-31
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Beijing Chao Yang Hospital
Collaborators: Second Affiliated Hospital, Zhejiang University, School of Medicine, The First Affiliated Hospital of Guangzhou Medical University, Shanxi Bethune Hospital, Henan Provincial People's Hospital, First Hospital of China Medical University, China-Japan Friendship Hospital, Beijing Tiantan Hospital, Second Xiangya Hospital of Central South University, Ruijin Hospital
Contact Information
Study Contact:
Kewu Huang, professor
8613601234681
kewuhuang@126.com
Kewu Huang
8613601234681
kewuhuang@126.com
Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University
Xiaoning Bu
8613641000837
Beijing Tiantan Hospital Affiliated to Capital Medical University
Interventions
  • Procedure: Individualized cluster management — Individualized cluster management for treatable traits
  • Procedure: Routine asthma treatment — Routine asthma treatment according to current guidelines
Study Locations (10 sites)
Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, Beijing Municipality 100020 China
Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, Beijing Municipality China
China-Japan Friendship Hospital, Beijing, Beijing Municipality China
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong China
Henan Provincial People's Hospital, Zhengzhou, Henan China
The Second Xiangya Hospital of Central South University, Changsha, Hunan China
The First Affiliated Hospital of China Medical University, Shenyang, Liaoning China
The First Affiliated Hospital of Guangzhou Medical University, Shanghai, Shanghai Municipality China
Shanxi Bethune Hospital, Taiyuan, Shanxi China
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang China
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years, and \<80 years with a definite diagnosis of asthma for at least 6 months * Patients met the 2024 GINA criteria for severe asthma, which was defined as "uncontrolled" asthma (frequent asthma symptoms, or frequent acute exacerbations) despite high-dose inhaled corticosteroids (ICS) plus long-acting β2-receptor antagonists (LABAs), or worsening of symptoms after slight tapering of high-dose therapy. * They were willing to accept multi-disciplinary and multi-dimensional evaluation and signed informed consent * Informed consent was obtained and patients were able to participate in the study and 6-month follow-up according to the protocol Exclusion Criteria: * The presence of numerous other lung tissue destructive diseases, such as severe bronchiectasis or pulmonary tuberculosis. * Chest surgery or abdominal surgery in the past 3 months * Eye surgery had been performed within the past 3 months * Myocardial infarction within the previous 3 months * Anti-tuberculosis treatment is ongoing * Women who are pregnant and lactating * Macrolide use within 4 weeks before the screening period * Treatment with anti-ige, anti-IL-5, or anti-IL-5R within 4 weeks before the screening period * Inhaled ICS+LABA+ long-acting anticholinergic agent (LAMA) for 4 weeks prior to the screening period 4. Allergy to macrolides * QTc interval prolongation \>480ms * Taking medications that interact with azithromycin, causing QTc prolongation or existing ECG abnormalities, may lead to arrhythmia
Conditions Asthma
Phase PHASE2
Enrollment 105
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), such as escitalopram are widely used for mood and anxiety disorders. However, they have also been explored, with promising findings, for a variety of disorders outside of psychiatry. Clinical studies of SSRIs in depressed people with asthma were associated with decreased asthma exacerbations and improvement in asthma control. In this study, the number of asthma exacerbations will be assessed as the primary outcome measure in patients using escitalopram vs. placebo.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Escitalopram — Escitalopram is an FDA-approved SSRI antidepressant that is administered by mouth
  • Drug: Placebo — Inactive placebo comparator

Primary Outcomes

  • Total number of severe asthma exacerbations (24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-05-19
Completion: 2029-06-01
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 105 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Texas Southwestern Medical Center
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigators:
  • Sherwood Brown, M.D, Ph.D, MBA (PRINCIPAL_INVESTIGATOR) - UTSW Medical Center
Contact Information
Study Contact:
Reagan Volzer, M.S.
214-645-6963
reagan.volzer@utsouthwestern.edu
Reagan Volzer, MS
214-645-6963
Reagan.Volzer@UTSouthwestern.edu
UT Southwestern, 1440 Empire Central, Ste. LD4.100
Génesis González Álvarez, MS
214-645-6967
Genesis.GonzalezAlvarez@UTSouthwestern.edu
UT Southwestern, 1440 Empire Central, Ste. LD4.100
Interventions
  • Drug: Escitalopram — Escitalopram is an FDA-approved SSRI antidepressant that is administered by mouth
  • Drug: Placebo — Inactive placebo comparator
Study Locations (1 sites)
UT Southwestern, 1440 Empire Central, Ste. LD4.100, Dallas, Texas 75247 United States
Eligibility Criteria
Inclusion Criteria: * Moderate to severe persistent asthma * Treatment with medium to high dose ICS and LABA therapy * Three or more severe asthma exacerbations (requiring ≥ 3 days of systemic corticosteroids) in the past year * Age 18-75 years old, male or female sex, English or Spanish speaking * Participants will be required to be clinically stable with no recent exacerbations, infections or changes in asthma controller therapy for at least 4 weeks before study entry * Biologic therapy for asthma (e.g., omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, tezepelumab) will be allowed if started at least 6 months prior to randomization Exclusion Criteria: * Current substance use disorder and/or current tobacco use or greater than 10 pack-years lifetime use * A current MDD episode as well as bipolar disorder, schizophrenia, or schizoaffective disorder * Vulnerable populations including intellectual disability or other severe cognitive impairment, inmates, pregnant or nursing women or women of childbearing age who will not use UT Southwestern IRB-approved methods of birth control or abstinence during the study * Currently taking an antidepressant (antidepressants that are not SSRIs nor SNRIs prescribed for an indication other than depression at subtherapeutic doses are acceptable) * High risk for suicide defined as \> 1 past suicide attempts or any attempt within the past 12 months * Severe or life-threatening medical illness that would make completion of study unlikely or clinically significant laboratory or ECG findings at baseline
Conditions Asthma
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to learn about the metabolomic profile of blood and urine in children 12-17 years with asthma. The main question it aims to answer is: • Are there metabolites in the blood and urine that are specific for asthma exacerbation? Participants already receive standard therapy as part of their regular medical care for asthma.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Interventions / Regimen

  • Drug: Standart medical treatment — No intervention, patients will recieve standard medical treatment

Primary Outcomes

  • inflammation biomarkers (baseline and 10 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-03-13
Completion: 2026-08
Eligibility
Age: 12 Years – 17 Years
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: I.M. Sechenov First Moscow State Medical University
Principal Investigators:
  • Natalia A. Geppe, MD, Doctor of M.Sc., Professor (PRINCIPAL_INVESTIGATOR) - I.M. Sechenov First Moscow State Medical University
Contact Information
Study Contact:
Natalia A. Geppe, MD, Doctor of M.Sc, Professor
+7-499-248-44-22
geppe@mail.ru
Irina V. Ozerskaia, MD, PhD
+7-926-387-25-12
ozerskaya_i_v@staff.sechenov.ru
Irina V. Ozerskaia, MD, PhD
+7-926-387-25-12
ozerskaya_i_v@staff.sechenov.ru
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Interventions
  • Drug: Standart medical treatment — No intervention, patients will recieve standard medical treatment
Study Locations (1 sites)
I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
Eligibility Criteria
Inclusion Criteria: * Age from 12 to 17 years old * Confirmed diagnosis of asthma * Informed voluntary consent to participate in the study Exclusion Criteria: * age under 12 years * no established diagnosis of asthma * concomitant severe somatic, metabolic, and endocrine diseases * patient's withdrawal of informed consent
Conditions Major Depressive Disorder (MDD), Gender ...
Phase Not Applicable
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

Depression is a common and serious mental health condition that affects mood, thoughts, behavior, and overall quality of life. It arises from a complex interaction of biological, psychological, and environmental factors. While depression is more frequently diagnosed in women, research suggests that men may experience and express depressive symptoms differently. Men are more likely to display symptoms such as irritability, anger, impulsivity, or increased alcohol use, and they may be less likely to seek professional psychological support due to social expectations and fear of stigma. Stigma-both self-stigma (internalized negative beliefs about having a mental illness) and perceived social stigma (concerns about being judged by others)-can negatively influence individuals' willingness to seek help and adhere to treatment. In addition, psychological resilience, defined as the ability to cope effectively with stress and adversity, may play an important role in how individuals experience depressive symptoms and respond to treatment. This study aims to compare women and men diagnosed with Major Depressive Disorder in terms of depression severity, gender-sensitive depressive symptoms, self-stigma, perceived social stigma, and levels of psychological resilience. It will also examine the relationships among these factors to better understand how gender-related differences influence the experience and management of depression. Findings from this study may contribute to improved recognition of gender-specific features of depression, reduction of stigma, and the development of more individualized and effective mental health interventions for both women and men.

Design

Study type: Observational Observational model: Case Only Time perspective: Cross Sectional

Primary Outcomes

  • Depression Severity (Baseline (single assessment))
  • Gender Differences in Gender-Sensitive Depressive Symptoms (Baseline (single assessment))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-06-01
Completion: 2026-11
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Eskisehir Osmangazi University
Contact Information
Study Contact:
İrem OZKAYNAK DAGLİ, Research assistant, M.D.
+90 0222 239 29 79
irem.ozkaynak@ogu.edu.tr
HARUN O SONKURT, Asst. Prof.
+90 0222 239 29 79
olcay.sonkurt@ogu.edu.tr
Interventions
N/A
Study Locations (1 sites)
the Department of Psychiatry Outpatient Clinic at Eskişehir Osmangazi University Faculty of Medicine, Eskişehir, Eskişehir 26040 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Male and female patients aged 18 to 65 years * Diagnosis of Major Depressive Disorder according to DSM-5 at the time of study participation * Provision of voluntary informed consent Exclusion Criteria: * Intellectual disability * Severe neurological disorders * Comorbid psychiatric diagnoses * Depressive disorder secondary to an organic medical condition * Depressive disorder secondary to substance use